These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 9674043

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Specific treatment of multiple sclerosis.
    Silberberg DH.
    Clin Neurosci; 1994; 2(3-4):271-4. PubMed ID: 7749898
    [Abstract] [Full Text] [Related]

  • 43. Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis.
    Serrano-Fernández P, Möller S, Goertsches R, Fiedler H, Koczan D, Thiesen HJ, Zettl UK.
    Autoimmunity; 2010 Mar; 43(2):172-8. PubMed ID: 19883335
    [Abstract] [Full Text] [Related]

  • 44. Down-regulation of survivin expression in T lymphocytes after interferon beta-1a treatment in patients with multiple sclerosis.
    Sharief MK, Semra YK.
    Arch Neurol; 2002 Jul; 59(7):1115-21. PubMed ID: 12117359
    [Abstract] [Full Text] [Related]

  • 45. [Beta-interferon and multiple sclerosis].
    Clanet M.
    Rev Neurol (Paris); 1993 Jul; 149(8-9):443-4. PubMed ID: 8009140
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. [Mechanisms of development of neurodegenerative processes in multiple sclerosis: neuroprotective influence of beta-interferons today and neurotrophic factors -- tomorrow].
    Boĭko AN, Petrov SV, Nesterova VA, Gusev EI.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003 Jul; (Spec No 2):83-90. PubMed ID: 12938641
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Interferons in MS Treatment: report from the Canadian MS Forum symposium, 26-29 August 2004, Québec, Canada.
    Duquette P.
    Int MS J; 2005 Apr; 12(1):33-4. PubMed ID: 15955277
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis.
    Petereit HF, Bamborschke S, Esse AD, Heiss WD.
    Mult Scler; 1997 Jun; 3(3):180-3. PubMed ID: 9310963
    [Abstract] [Full Text] [Related]

  • 55. Recent advances in immunology in multiple sclerosis.
    Liblau RS, Fontaine B.
    Curr Opin Neurol; 1998 Aug; 11(4):293-8. PubMed ID: 9725073
    [Abstract] [Full Text] [Related]

  • 56. Multiple sclerosis: where will we be in 2020?
    Miller AE.
    Mt Sinai J Med; 2011 Aug; 78(2):268-79. PubMed ID: 21425270
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Autoimmune hepatitis and multiple sclerosis: a coincidental association?
    de Seze J, Canva-Delcambre V, Fajardy I, Delalande S, Stojkovic T, Godet E, Vermersch P.
    Mult Scler; 2005 Dec; 11(6):691-3. PubMed ID: 16320729
    [Abstract] [Full Text] [Related]

  • 59. [Endogenous biological retranslation in current clinical and biological studies].
    Cheknev SB.
    Vestn Ross Akad Med Nauk; 2003 Dec; (4):28-34. PubMed ID: 12741357
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.